# Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

> **NCT00390156** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 35 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** cyclophosphamide
- **DRUG:** imatinib

## Key facts

- **NCT ID:** NCT00390156
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390156, "Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00390156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*